Scribe Therapeutics, Inc. - 10-Q Filing
Scribe Therapeutics reports Q3 financial results featuring significant R&D and G&A expenditures alongside ongoing licensing revenue from Sanofi and Prevail agreements.
Tickers: $SCTX
More Regulatory news
- Nakamoto Inc. - 8-K Filing
- enCore Energy Corp. - 10-Q Filing
- Cibus, Inc. - 10-Q Filing
- Spero Therapeutics, Inc. - 10-Q Filing
- PepGen Inc. - 8-K Filing
- WhiteHawk Minerals Corp. - 8-K Filing
- Altimmune, Inc. - 10-Q Filing
- LifeStance Health Group, Inc. - 8-K Filing
- Net Power Inc. - 10-Q Filing
- FIRST KEYSTONE CORP - 10-Q Filing